Given that the vessel normalization induced by anti-angiogenic agents ameliorates tumor hypoxia and facilitates the immune functions of immunocytes, studies on other cancers have explored the feasibility of implementing a dual blockade of VEGF and immune checkpoints [33, 34]. This evidence concerns the gene VEGFA and neoplasm.